Literature DB >> 10662873

Hepatic fibrosis in rheumatoid arthritis patients treated with methotrexate: application of a new semi-quantitative scoring system.

S Richard1, S Guerret, F Gerard, J G Tebib, E Vignon.   

Abstract

OBJECTIVE: Evaluation of hepatic lesions in patients treated with methotrexate (MTX) generally used the Roenigk histological score. However, the sensitivity of the method for hepatic fibrosis assessment has been discussed. The semi-quantitative histological scoring system (SSS) offers a sensitive and specific evaluation of liver fibrosis. Both scores have been evaluated in liver biopsies of patients with rheumatoid arthritis.
METHODS: Seventy-four liver biopsies were obtained in 57 rheumatoid arthritis patients before initiation of MTX (group 1, 38 cases), in cases of a persistently high level of transaminases during 1 yr of treatment (group 2, 10 cases) and after a MTX total dose of 2 g (group 3, 26 cases). Eleven biopsies of groups 1 and 3 originated from the same patient in 11 cases. Specimens were examined blindly by two anatomopathologists. The three groups were compared with an ANOVA. Sequential biopsies performed in 11 patients were compared with the Wilcoxon paired test.
RESULTS: The Roenigk score and the SSS were significantly correlated (P<0.0001). Only a mild fibrosis was found in 33.8% (25/74) of the biopsies with the Roenigk score. Liver fibrosis, graded as mild (48.6%), moderate (41.8%) or severe (4%), was demonstrated in 94.6% (70/74) of the biopsies with the SSS. The Roenigk score and the SSS of the three patient groups were not statistically significantly different. The scores did not progress in the 11 patients who had serial biopsies.
CONCLUSION: SSS is much more sensitive than the Roenigk score for the evaluation of hepatic fibrosis. However, SSS did not show progression of hepatic fibrosis in patients with rheumatoid arthritis treated with MTX.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10662873     DOI: 10.1093/rheumatology/39.1.50

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  5 in total

1.  Liver cirrhosis in selected autoimmune diseases: a nationwide cohort study in Taiwan.

Authors:  Chien-Hsueh Tung; Ning-Seng Lai; Ming-Chi Lu; Ching-Chih Lee
Journal:  Rheumatol Int       Date:  2015-09-25       Impact factor: 2.631

2.  Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes.

Authors:  Emilie Quintin; Jean-Yves Scoazec; Hubert Marotte; Pierre Miossec
Journal:  Arthritis Res Ther       Date:  2010-07-16       Impact factor: 5.156

3.  Preventive effect of halofuginone on concanavalin A-induced liver fibrosis.

Authors:  Jie Liang; Bei Zhang; Ruo-wu Shen; Jia-Bao Liu; Mei-hua Gao; Ying Li; Yuan-Yuan Li; Wen Zhang
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

4.  Methotrexate is not associated with increased liver cirrhosis in a population-based cohort of rheumatoid arthritis patients with chronic hepatitis B.

Authors:  Kuo-Tung Tang; Wei-Ting Hung; Yi-Hsing Chen; Ching-Heng Lin; Der-Yuan Chen
Journal:  Sci Rep       Date:  2016-03-01       Impact factor: 4.379

5.  Prevalence and risk factors of moderate to severe hepatic steatosis in patients with rheumatoid arthritis: an ultrasonography cross-sectional case-control study.

Authors:  Gian Luca Erre; Floriana Castagna; Assunta Sauchella; Pierluigi Meloni; Arduino Aleksander Mangoni; Giuseppina Farina; Richard Woodman; Maria Pina Dore; Gianpaolo Vidili
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-11-18       Impact factor: 5.346

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.